Skip to Content
Merck

KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D.

eLife (2019-05-18)
Sawan Kumar Jha, Khushbu Rauniyar, Ewa Chronowska, Kenny Mattonet, Eunice Wairimu Maina, Hannu Koistinen, Ulf-Håkan Stenman, Kari Alitalo, Michael Jeltsch
ABSTRACT

Vascular endothelial growth factor-C (VEGF-C) acts primarily on endothelial cells, but also on non-vascular targets, for example in the CNS and immune system. Here we describe a novel, unique VEGF-C form in the human reproductive system produced via cleavage by kallikrein-related peptidase 3 (KLK3), aka prostate-specific antigen (PSA). KLK3 activated VEGF-C specifically and efficiently through cleavage at a novel N-terminal site. We detected VEGF-C in seminal plasma, and sperm liquefaction occurred concurrently with VEGF-C activation, which was enhanced by collagen and calcium binding EGF domains 1 (CCBE1). After plasmin and ADAMTS3, KLK3 is the third protease shown to activate VEGF-C. Since differently activated VEGF-Cs are characterized by successively shorter N-terminal helices, we created an even shorter hypothetical form, which showed preferential binding to VEGFR-3. Using mass spectrometric analysis of the isolated VEGF-C-cleaving activity from human saliva, we identified cathepsin D as a protease that can activate VEGF-C as well as VEGF-D.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
ANTI-VEGFC antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
ANTI-VEGFC antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
ANTI-VEGFC (VEGF3) (CENTER M263) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution